Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
2.
Blood ; 130(17): 1946-1948, 2017 10 26.
Article in English | MEDLINE | ID: mdl-28887325

ABSTRACT

Novel curative therapies using genetic transfer of normal globin-producing genes into autologous hematopoietic stem cells (HSCs) are in clinical trials for patients with sickle cell disease (SCD). The percentage of transferred globin necessary to cure SCD is currently not known. In the setting of allogeneic nonmyeloablative HSC transplants (HSCTs), stable mixed chimerism is sufficient to reverse the disease. We regularly monitored 67 patients after HSCT. After initially robust engraftment, 3 of these patients experienced declining donor myeloid chimerism (DMC) levels with eventual return of disease. From this we discovered that 20% DMC is necessary to reverse the sickle phenotype. We subsequently developed a mathematical model to test the hypothesis that the percentage of DMC necessary is determined solely by differences between donor and recipient red blood cell (RBC) survival times. In our model, the required 20% DMC can be entirely explained by the large differences between donor and recipient RBC survival times. Our model predicts that the requisite DMC and therefore necessary level of transferred globin is lowest in patients with the highest reticulocyte counts and concomitantly shortened RBC lifespans.


Subject(s)
Anemia, Sickle Cell/pathology , Anemia, Sickle Cell/therapy , Hematopoietic Stem Cell Transplantation , Myeloid Cells/pathology , Tissue Donors , Transplantation Chimera/metabolism , Adult , Hemoglobin, Sickle/metabolism , Homozygote , Humans , Phenotype , Transplantation, Homologous , Young Adult
3.
Blood Adv ; 1(11): 652-661, 2017 Apr 25.
Article in English | MEDLINE | ID: mdl-29296707

ABSTRACT

Peripheral blood stem cell transplantation (PBSCT) offers a curative option for sickle cell disease (SCD). Although HLA-matched sibling transplantation is promising, the vast majority of patients lack such a donor. We sought to develop a novel nonmyeloablative HLA-haploidentical PBSCT approach that could safely be used for patients with severe organ damage. Based on findings in our preclinical model, we developed a phase 1/2 trial using alemtuzumab, 400 cGy total body irradiation, and escalating doses of posttransplant cyclophosphamide (PT-Cy): 0 mg/kg in cohort 1, 50 mg/kg in cohort 2, and 100 mg/kg in cohort 3. A total of 21 patients with SCD and 2 with ß-thalassemia received a transplant. The mean hematopoietic cell transplant-specific comorbidity index of 6 reflected patients with cirrhosis, heart failure, and end-stage renal disease. The engraftment rate improved from 1 (33%) of 3 in cohort 1 to 5 (63%) of 8 in cohort 2 and 10 (83%) of 12 in cohort 3. Percentage of donor myeloid and CD3 chimerism also improved with subsequent cohorts. There was no transplant-related mortality, and overall survival was 87%. At present, 0% in cohort 1, 25% in cohort 2, and 50% in cohort 3 remain free of their disease. There was no grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). Therefore, PT-Cy improves engraftment and successfully prevents severe GVHD after nonmyeloablative conditioning in patients with SCD who are at high risk for early mortality. Additional strategies are necessary to decrease the graft rejection rate and achieve a widely available cure for all patients with SCD. This trial was registered at www.clinicaltrials.gov as #NCT00977691.

4.
PLoS One ; 10(11): e0141706, 2015.
Article in English | MEDLINE | ID: mdl-26576059

ABSTRACT

BACKGROUND: Adults with sickle cell anemia (HbSS) are inconsistently treated with hydroxyurea. OBJECTIVES: We retrospectively evaluated the effects of elevating fetal hemoglobin with hydroxyurea on organ damage and survival in patients enrolled in our screening study between 2001 and 2010. METHODS: An electronic medical record facilitated development of a database for comparison of study parameters based on hydroxyurea exposure and dose. This study is registered with ClinicalTrials.gov, number NCT00011648. RESULTS: Three hundred eighty-three adults with homozygous sickle cell disease were analyzed with 59 deaths during study follow-up. Cox regression analysis revealed deceased subjects had more hepatic dysfunction (elevated alkaline phosphatase, Hazard Ratio = 1.005, 95% CI 1.003-1.006, p<0.0.0001), kidney dysfunction (elevated creatinine, Hazard Ratio = 1.13, 95% CI 1.00-1.27, p = 0.043), and cardiopulmonary dysfunction (elevated tricuspid jet velocity on echocardiogram, Hazard Ratio = 2.22, 1.23-4.02, p = 0.0082). Sixty-six percent of subjects were treated with hydroxyurea, although only 66% of those received a dose within the recommended therapeutic range. Hydroxyurea use was associated with improved survival (Hazard Ratio = 0.58, 95% CI 0.34-0.97, p = 0.040). This effect was most pronounced in those taking the recommended dose of 15-35 mg/kg/day (Hazard Ratio 0.36, 95% CI 0.17-0.73, p = 0.0050). Hydroxyurea use was not associated with changes in organ function over time. Further, subjects with higher fetal hemoglobin responses to hydroxyurea were more likely to survive (p = 0.0004). While alkaline phosphatase was lowest in patients with the best fetal hemoglobin response (95.4 versus 123.6, p = 0.0065 and 96.1 versus 113.6U/L, p = 0.041 at first and last visits, respectively), other markers of organ damage were not consistently improved over time in patients with the highest fetal hemoglobin levels. CONCLUSIONS: Our data suggest that adults should be treated with the maximum tolerated hydroxyurea dose, ideally before organ damage occurs. Prospective studies are indicated to validate these findings.


Subject(s)
Anemia, Sickle Cell/drug therapy , Antisickling Agents/therapeutic use , Hydroxyurea/therapeutic use , Adolescent , Adult , Aged , Anemia, Sickle Cell/blood , Anemia, Sickle Cell/mortality , Antisickling Agents/pharmacology , Female , Fetal Hemoglobin/metabolism , Humans , Hydroxyurea/pharmacology , Male , Maximum Tolerated Dose , Middle Aged , Proportional Hazards Models , Retrospective Studies , Treatment Outcome , Young Adult
5.
JAMA ; 312(1): 48-56, 2014 Jul 02.
Article in English | MEDLINE | ID: mdl-25058217

ABSTRACT

IMPORTANCE: Myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) is curative for children with severe sickle cell disease, but toxicity may be prohibitive for adults. Nonmyeloablative transplantation has been attempted with degrees of preparative regimen intensity, but graft rejection and graft-vs-host disease remain significant. OBJECTIVE: To determine the efficacy, safety, and outcome on end-organ function with this low-intensity regimen for sickle cell phenotype with or without thalassemia. DESIGN, SETTING, AND PARTICIPANTS: From July 16, 2004, to October 25, 2013, 30 patients aged 16-65 years with severe disease enrolled in this nonmyeloablative transplant study, consisting of alemtuzumab (1 mg/kg in divided doses), total-body irradiation (300 cGy), sirolimus, and infusion of unmanipulated filgrastim mobilized peripheral blood stem cells (5.5-31.7 × 10(6) cells/kg) from human leukocyte antigen-matched siblings. MAIN OUTCOMES AND MEASURES: The primary end point was treatment success at 1 year after the transplant, defined as a full donor-type hemoglobin for patients with sickle cell disease and transfusion independence for patients with thalassemia. The secondary end points were the level of donor leukocyte chimerism; incidence of acute and chronic graft-vs-host disease; and sickle cell-thalassemia disease-free survival, immunologic recovery, and changes in organ function, assessed by annual brain imaging, pulmonary function, echocardiographic image, and laboratory testing. RESULTS: Twenty-nine patients survived a median 3.4 years (range, 1-8.6), with no nonrelapse mortality. One patient died from intracranial bleeding after relapse. As of October 25, 2013, 26 patients (87%) had long-term stable donor engraftment without acute or chronic graft-vs-host disease. The mean donor T-cell level was 48% (95% CI, 34%-62%); the myeloid chimerism levels, 86% (95% CI, 70%-100%). Fifteen engrafted patients discontinued immunosuppression medication with continued stable donor chimerism and no graft-vs-host disease. The normalized hemoglobin and resolution of hemolysis among engrafted patients were accompanied by stabilization in brain imaging, a reduction of echocardiographic estimates of pulmonary pressure, and allowed for phlebotomy to reduce hepatic iron. The mean annual hospitalization rate was 3.23 (95% CI, 1.83-4.63) the year before, 0.63 (95% CI, 0.26-1.01) the first year after, 0.19 (95% CI, 0-0.45) the second year after, and 0.11 (95% CI, 0.04-0.19) the third year after transplant. For patients taking long-term narcotics, the mean use per week was 639 mg (95% CI, 220-1058) of intravenous morphine-equivalent dose the week of their transplants and 140 mg (95% CI, 56-225) 6 months after transplant. There were 38 serious adverse events: pain and related management, infections, abdominal events, and sirolimus related toxic effects. CONCLUSIONS AND RELEVANCE: Among 30 patients with sickle cell phenotype with or without thalassemia who underwent nonmyeloablative allogeneic HSCT, the rate of stable mixed-donor chimerism was high and allowed for complete replacement with circulating donor red blood cells among engrafted participants. Further accrual and follow-up are required to assess longer-term clinical outcomes, adverse events, and transplant tolerance. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00061568.


Subject(s)
Anemia, Sickle Cell/therapy , Antibodies, Monoclonal, Humanized/administration & dosage , Hematopoietic Stem Cell Transplantation , Immunosuppressive Agents/administration & dosage , Sirolimus/administration & dosage , beta-Thalassemia/therapy , Adolescent , Adult , Aged , Alemtuzumab , Anemia, Sickle Cell/complications , Chimerism , Erythrocytes , Female , Filgrastim , Graft vs Host Disease , Granulocyte Colony-Stimulating Factor , HLA Antigens , Hematopoietic Stem Cell Mobilization , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/methods , Humans , Infections/etiology , Male , Middle Aged , Pain/etiology , Prospective Studies , Recombinant Proteins , Sirolimus/adverse effects , Transplantation Conditioning , Transplantation, Homologous , Treatment Outcome , Whole-Body Irradiation , Young Adult , beta-Thalassemia/complications
6.
Blood ; 119(24): 5671-3, 2012 Jun 14.
Article in English | MEDLINE | ID: mdl-22547579

ABSTRACT

Peripheral blood stem cell (PBSC) infusions are associated with complications such as elevated blood pressure and decreased creatinine clearance. Patients with sickle cell disease experience similar manifestations, and some have postulated release of plasma-free hemoglobin with subsequent nitric oxide consumption as causative. We sought to evaluate whether the infusion of PBSC grafts containing lysed red blood cells (RBCs) leads to the toxicity observed in transplant subjects. We report a prospective cohort study of 60 subjects divided into 4 groups based on whether their infusions contained dimethyl sulfoxide (DMSO) and lysed RBCs, no DMSO and fresh RBCs, DMSO and no RBCs, or saline. Our primary end point, change in maximum blood pressure compared with baseline, was not significantly different among groups. Tricuspid regurgitant velocity and creatinine levels also did not differ significantly among groups. Our data do not support free hemoglobin as a significant contributor to toxicity associated with PBSC infusions. This study was registered at clinicaltrials.gov (NCT00631787).


Subject(s)
Anemia, Sickle Cell/physiopathology , Anemia, Sickle Cell/therapy , Erythrocytes/physiology , Hemolysis/physiology , Peripheral Blood Stem Cell Transplantation , Blood Pressure/physiology , Haptoglobins/metabolism , Heart Rate/physiology , Humans , Infusions, Intravenous , L-Lactate Dehydrogenase/metabolism
7.
JAMA ; 305(9): 893-902, 2011 Mar 02.
Article in English | MEDLINE | ID: mdl-21364138

ABSTRACT

CONTEXT: Inhaled nitric oxide has shown evidence of efficacy in mouse models of sickle cell disease (SCD), case series of patients with acute chest syndrome, and 2 small placebo-controlled trials for treatment of vaso-occlusive pain crisis (VOC). OBJECTIVE: To determine whether inhaled nitric oxide gas reduces the duration of painful crisis in patients with SCD who present to the emergency department or hospital for care. DESIGN, SETTING, AND PARTICIPANTS: Prospective, multicenter, double-blind, randomized, placebo-controlled clinical trial for up to 72 hours of inhaled nitric oxide gas vs inhaled nitrogen placebo in 150 participants presenting with VOC of SCD at 11 centers between October 5, 2004, and December 22, 2008. Intervention Inhaled nitric oxide gas vs inhaled nitrogen placebo. MAIN OUTCOME MEASURES: The primary end point was the time to resolution of painful crisis, defined by (1) freedom from parenteral opioid use for 5 hours; (2) pain relief as assessed by visual analog pain scale scores of 6 cm or lower (on 0-10 scale); (3) ability to walk; and (4) patient's and family's decision, with physician consensus, that the remaining pain could be managed at home. RESULTS: There was no significant change in the primary end point between the nitric oxide and placebo groups, with a median time to resolution of crisis of 73.0 hours (95% confidence interval [CI], 46.0-91.0) and 65.5 hours (95% CI, 48.1-84.0), respectively (P = .87). There were no significant differences in secondary outcome measures, including length of hospitalization, visual analog pain scale scores, cumulative opioid usage, and rate of acute chest syndrome. Inhaled nitric oxide was well tolerated, with no increase in serious adverse events. Increases in venous methemoglobin concentration confirmed adherence and randomization but did not exceed 5% in any study participant. Significant increases in plasma nitrate occurred in the treatment group, but there were no observed increases in plasma or whole blood nitrite. CONCLUSION: Among patients with SCD hospitalized with VOC, the use of inhaled nitric oxide compared with placebo did not improve time to crisis resolution. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00094887.


Subject(s)
Anemia, Sickle Cell/complications , Endothelium-Dependent Relaxing Factors/administration & dosage , Nitric Oxide/administration & dosage , Pain/drug therapy , Administration, Inhalation , Adolescent , Adult , Double-Blind Method , Female , Humans , Male , Pain/etiology , Pain Measurement , Prospective Studies , Treatment Outcome , Young Adult
8.
Br J Haematol ; 147(5): 737-43, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19775299

ABSTRACT

Pulmonary Hypertension is a serious complication of sickle cell disease (SCD), with high morbidity and mortality. Endothelin (ET)-1, a potent vasoconstrictor elevated in SCD, acts through the ET receptors (ETR), ETR-A and ETR-B. Bosentan and ambrisentan are ETR blockers used in primary pulmonary hypertension. We report on the use of ETR blocking agents in a cohort of 14 high-risk SCD adult patients with pulmonary hypertension. Patients underwent right heart catheterization, 6-min walk test, echocardiogram, physical examination and blood work-up before starting ETR blockers. Eight patients received ETR blockers as initial therapy; six patients were already taking sildenafil. Over more than 6 months of therapy, sequential measurements of 6-min walk distance increased significantly (baseline 357 +/- 22 to 398 +/- 18 m at 5-6 months, P < 0.05). Downward trends were observed for amino-terminal brain natriuretic peptide and tricuspid regurgitant velocity. Pulmonary artery mean pressures decreased in three patients that had repeat right heart catheterization (44-38 mmHg). Adverse events were: increased serum alanine aminotransferase (2), peripheral oedema (4), rash (1), headache (3), decreased haemoglobin (2). Therapy was stopped in two patients who were switched then to the other ETR blocker agent. These data suggest preliminary evidence for the benefit of bosentan and ambrisentan in pulmonary hypertension in SCD.


Subject(s)
Anemia, Sickle Cell/complications , Antihypertensive Agents/therapeutic use , Endothelin Receptor Antagonists , Hypertension, Pulmonary/drug therapy , Adult , Antihypertensive Agents/adverse effects , Bosentan , Cardiac Catheterization , Drug Evaluation , Drug Therapy, Combination , Exercise Test/methods , Humans , Hypertension, Pulmonary/etiology , Middle Aged , Phenylpropionates/adverse effects , Phenylpropionates/therapeutic use , Piperazines/adverse effects , Piperazines/therapeutic use , Purines/adverse effects , Purines/therapeutic use , Pyridazines/adverse effects , Pyridazines/therapeutic use , Retrospective Studies , Sildenafil Citrate , Sulfonamides/adverse effects , Sulfonamides/therapeutic use , Sulfones/adverse effects , Sulfones/therapeutic use , Treatment Outcome
9.
Am J Respir Crit Care Med ; 175(12): 1272-9, 2007 Jun 15.
Article in English | MEDLINE | ID: mdl-17379852

ABSTRACT

RATIONALE: Although pulmonary hypertension (PH) is a common complication of sickle cell disease (SCD) associated with high mortality, there exist few data characterizing hemodynamics and cardiopulmonary function in this population. OBJECTIVES: To characterize hemodynamics and cardiopulmonary function in patients with SCD with and without PH. METHODS: Patients with SCD with PH (n = 26) were compared with control subjects with SCD but without PH (n = 17), matched for age, hemoglobin levels, and fetal hemoglobin levels. MEASUREMENTS AND MAIN RESULTS: Upon catheterization, 54% of the patients with PH had pulmonary arterial hypertension, and 46% had pulmonary venous hypertension. When compared with control subjects, patients with PH exhibited lower six-minute-walk distance (435 +/- 31 vs. 320 +/- 20 m, p = 0.002) and oxygen consumption (50 +/- 3% vs. 41 +/- 2% of predicted, p = 0.02), and also had mild restrictive lung disease and more perfusion abnormalities on radionuclide lung scans. The six-minute-walk distance in this population inversely correlated with tricuspid regurgitant jet velocity (r = -0.55, p < 0.001), and mean pulmonary artery pressure (r = -0.57, p < 0.001), and directly correlated with maximal oxygen consumption (r = 0.49, p = 0.004), even after adjustment for hemoglobin, supporting an independent contribution of increasing pulmonary artery pressures to loss of exercise capacity. CONCLUSIONS: Patients with SCD-associated PH have both pulmonary arterial and venous PH associated with severe limitations in exercise capacity, likely compounded by interstitial lung fibrosis and severe anemia. These data support the use of the six-minute-walk distance as an index of PH and cardiopulmonary function in patients with SCD.


Subject(s)
Anemia, Sickle Cell/physiopathology , Hypertension, Pulmonary/physiopathology , Adult , Anemia, Sickle Cell/complications , Cardiac Catheterization , Cardiac Output , Exercise Test , Exercise Tolerance , Female , Fibrosis , Humans , Hypertension, Pulmonary/diagnostic imaging , Hypertension, Pulmonary/etiology , Lung/diagnostic imaging , Lung/pathology , Male , Middle Aged , Oxygen Consumption , Respiratory Function Tests , Tomography, X-Ray Computed , Ventilation-Perfusion Ratio
10.
J Am Coll Cardiol ; 49(4): 472-9, 2007 Jan 30.
Article in English | MEDLINE | ID: mdl-17258093

ABSTRACT

OBJECTIVES: The goal of this study was to characterize left ventricular diastolic function in the sickle cell disease (SCD) population and to relate echocardiographic measures of dysfunction with pulmonary hypertension and mortality. BACKGROUND: Pulmonary hypertension has been identified as a predictor of death in the adult SCD population. Although diastolic dysfunction is also observed in this population, its prevalence, association with high pulmonary artery systolic pressure, and attributable mortality remain unknown. METHODS: Diastolic function assessment using tissue Doppler imaging was performed in a group of 141 SCD patients. Conventional echocardiographic parameters of diastolic function were performed in a total of 235 SCD patients. RESULTS: Diastolic dysfunction was present in 18% of patients. A combination of diastolic dysfunction and pulmonary hypertension was present in 11% of patients, and diastolic dysfunction accounted for only 10% to 20% of the variability in tricuspid regurgitation (TR) jet velocity. Diastolic dysfunction, as reflected by a low E/A ratio, was associated with mortality with a risk ratio of 3.5 (95% confidence interval 1.5 to 8.4, p < 0.001), even after adjustment for tricuspid regurgitation (TR) jet velocity. The presence of both diastolic dysfunction and pulmonary hypertension conferred a risk ratio for death of 12.0 (95% confidence interval 3.8 to 38.1, p < 0.001). CONCLUSIONS: Diastolic dysfunction and pulmonary hypertension each contribute independently to prospective mortality in patients with SCD. Patients with both risk factors have an extremely poor prognosis. These data support the implementation of echocardiographic screening of adult patients with SCD to identify high-risk individuals for further evaluation.


Subject(s)
Anemia, Sickle Cell/mortality , Anemia, Sickle Cell/physiopathology , Diastole , Hypertension, Pulmonary/physiopathology , Adolescent , Adult , Aged , Anemia, Sickle Cell/complications , Echocardiography, Doppler , Female , Heart Ventricles/diagnostic imaging , Heart Ventricles/pathology , Humans , Hypertension, Pulmonary/complications , Male , Middle Aged , Risk Factors , Ventricular Function, Left
11.
Br J Haematol ; 136(2): 319-25, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17156401

ABSTRACT

Pulmonary hypertension is associated with sudden death and is a risk factor for mortality in adult patients with sickle cell disease. The high mortality despite only mild-to-moderate increases in pulmonary vascular resistance remains an unresolved paradox. Accordingly, little is known about the cardiovascular effects of stressors, such as vaso-occlusive pain crisis (VOC) and exercise, which may acutely increase pulmonary pressures and impair right heart function. We therefore evaluated pulmonary artery pressures by echocardiogram in 25 patients with sickle cell disease in steady-state and during VOC, and by right heart catheterisation with exercise in a second cohort of 21 patients to determine whether pulmonary hypertension worsens during acute cardiopulmonary stress. TRV increased during VOC (P < 0.001), and the increased pulmonary pressures during VOC were associated with decreases in haemoglobin levels (P < 0.001), and increases in lactate dehydrogenase (P < 0.001) and plasma haemoglobin levels (P = 0.03). During exercise stress performed during cardiac catheterisation, mean pulmonary artery pressures (P < 0.001) and pulmonary vascular resistance increased (P < 0.001) in all subjects. These data suggest that acute elevations in pulmonary pressures during VOC or exercise may contribute to morbidity and mortality in patients with sickle cell disease.


Subject(s)
Anemia, Sickle Cell/complications , Hypertension, Pulmonary/etiology , Pain/etiology , Vascular Diseases/complications , Adult , Analysis of Variance , Anemia, Sickle Cell/diagnostic imaging , Blood Pressure , Cardiac Catheterization , Echocardiography , Exercise , Female , Hemoglobins/analysis , Humans , Hypertension, Pulmonary/diagnostic imaging , L-Lactate Dehydrogenase/blood , Male , Middle Aged , Pain/diagnostic imaging , Vascular Diseases/diagnostic imaging , Vascular Resistance
12.
Br J Haematol ; 130(6): 943-53, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16156864

ABSTRACT

Endothelial cell adhesion molecules orchestrate the recruitment and binding of inflammatory cells to vascular endothelium. With endothelial dysfunction and vascular injury, the levels of endothelial bound and soluble adhesion molecules increase. Such expression is modulated by nitric oxide (NO), and in patients with sickle cell disease (SCD), these levels are inversely associated with measures of NO bioavailability. To further evaluate the role of endothelial dysfunction in a population study of SCD, we have measured the levels of soluble endothelium-derived adhesion molecules in the plasma specimens of 160 adult patients with SCD during steady state. Consistent with a link between endothelial dysfunction and end-organ disease, we found that higher levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) were associated with markers indicating renal dysfunction and hepatic impairment. Analysis of soluble intercellular cell adhesion molecule-1 (sICAM-1), sE-selectin and sP-selectin levels indicated partially overlapping associations with sVCAM-1, with an additional association with inflammatory stress and triglyceride levels. Importantly, increased soluble adhesion molecule expression correlated with severity of pulmonary hypertension, a clinical manifestation of endothelial dysfunction. Soluble VCAM-1, ICAM-1, and E-selectin were independently associated with the risk of mortality in this cohort. Our data are consistent with steady state levels of soluble adhesion molecules as markers of pulmonary hypertension and risk of death.


Subject(s)
Anemia, Sickle Cell/blood , Anemia, Sickle Cell/complications , Cell Adhesion Molecules/blood , Hypertension, Pulmonary/etiology , Adolescent , Adult , Aged , Anemia, Sickle Cell/physiopathology , Biomarkers/blood , Cell Adhesion Molecules/drug effects , E-Selectin/blood , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiopathology , Female , Humans , Hydroxyurea/pharmacology , Hypertension, Pulmonary/blood , Intercellular Adhesion Molecule-1/blood , Male , Middle Aged , Solubility , Survival Analysis , Vascular Cell Adhesion Molecule-1/blood
13.
Br J Haematol ; 130(3): 445-53, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16042696

ABSTRACT

UNLABELLED: Pulmonary hypertension is a frequent complication of sickle cell disease that is associated with haemolysis, impaired nitric oxide bioavailability and high mortality. We sought to evaluate the safety and efficacy of selective pulmonary vasodilators and antiproliferative agents in this at-risk population. After optimising sickle cell disease therapy to stabilise haemoglobin and fetal haemoglobin levels, we evaluated the safety and efficacy of sildenafil in 12 patients with sickle cell disease and pulmonary hypertension. Sildenafil therapy (mean duration 6 +/- 1 months) decreased the estimated pulmonary artery systolic pressure [50 +/- 4 to 41 +/- 3 mmHg; difference 9 mmHg, 95% confidence interval (CI): 0.3-17, P = 0.043] and increased the 6-min walk distance (384 +/- 30 to 462 +/- 28 m; difference 78 m, 95% CI: 40-117, P = 0.0012). Transient headaches occurred in two patients and transient eye-lid oedema in four patients. No episodes of priapism occurred in the three men in the study; two of them were on chronic exchange transfusions and one had erectile dysfunction. IN CONCLUSION: (1) sickle cell disease patients with anaemia and pulmonary hypertension have significant exercise limitation; (2) the 6-min walk distance may be a valid endpoint in this population; (3) therapy with sildenafil appears safe and improves pulmonary hypertension and exercise capacity. Additional phase I studies in males with sickle cell disease followed by phase II/III placebo controlled trials evaluating the safety and efficacy of sildenafil therapy in sickle cell disease patients with pulmonary hypertension are warranted.


Subject(s)
Anemia, Sickle Cell/complications , Hypertension, Pulmonary/complications , Piperazines/therapeutic use , Vasodilator Agents/therapeutic use , Adult , Anemia, Sickle Cell/drug therapy , Anemia, Sickle Cell/physiopathology , Cardiac Catheterization , Echocardiography , Exercise Test , Female , Humans , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/physiopathology , Male , Middle Aged , Pilot Projects , Purines , Reproducibility of Results , Sildenafil Citrate , Statistics, Nonparametric , Sulfones , Systole , Vascular Resistance/drug effects
14.
N Engl J Med ; 350(9): 886-95, 2004 Feb 26.
Article in English | MEDLINE | ID: mdl-14985486

ABSTRACT

BACKGROUND: The prevalence of pulmonary hypertension in adults with sickle cell disease, the mechanism of its development, and its prospective prognostic significance are unknown. METHODS: We performed Doppler echocardiographic assessments of pulmonary-artery systolic pressure in 195 consecutive patients (82 men and 113 women; mean [+/-SD] age, 36+/-12 years). Pulmonary hypertension was prospectively defined as a tricuspid regurgitant jet velocity of at least 2.5 m per second. Patients were followed for a mean of 18 months, and data were censored at the time of death or loss to follow-up. RESULTS: Doppler-defined pulmonary hypertension occurred in 32 percent of patients. Multiple logistic-regression analysis, with the use of the dichotomous variable of a tricuspid regurgitant jet velocity of less than 2.5 m per second or 2.5 m per second or more, identified a self-reported history of cardiovascular or renal complications, increased systolic blood pressure, high lactate dehydrogenase levels (a marker of hemolysis), high levels of alkaline phosphatase, and low transferrin levels as significant independent correlates of pulmonary hypertension. The fetal hemoglobin level, white-cell count, and platelet count and the use of hydroxyurea therapy were unrelated to pulmonary hypertension. A tricuspid regurgitant jet velocity of at least 2.5 m per second, as compared with a velocity of less than 2.5 m per second, was strongly associated with an increased risk of death (rate ratio, 10.1; 95 percent confidence interval, 2.2 to 47.0; P<0.001) and remained so after adjustment for other possible risk factors in a proportional-hazards regression model. CONCLUSIONS: Pulmonary hypertension, diagnosed by Doppler echocardiography, is common in adults with sickle cell disease. It appears to be a complication of chronic hemolysis, is resistant to hydroxyurea therapy, and confers a high risk of death. Therapeutic trials targeting this population of patients are indicated.


Subject(s)
Anemia, Sickle Cell/complications , Cause of Death , Hypertension, Pulmonary/etiology , Adult , Anemia, Sickle Cell/drug therapy , Anemia, Sickle Cell/mortality , Antisickling Agents/therapeutic use , Blood Pressure , Drug Resistance , Echocardiography, Doppler , Female , Hemolysis , Humans , Hydroxyurea/therapeutic use , Hypertension, Pulmonary/classification , Hypertension, Pulmonary/diagnostic imaging , Hypertension, Pulmonary/physiopathology , Logistic Models , Male , Prevalence , Pulmonary Artery/diagnostic imaging , Pulmonary Artery/physiopathology , Risk Factors , Survival Rate , Tricuspid Valve Insufficiency/diagnostic imaging , Tricuspid Valve Insufficiency/physiopathology , Ventricular Function
15.
Circulation ; 107(2): 271-8, 2003 Jan 21.
Article in English | MEDLINE | ID: mdl-12538427

ABSTRACT

BACKGROUND: Although reduced endothelial nitric oxide (NO) bioavailability has been demonstrated in arteriosclerotic vascular disease, the integrity of this system in sickle cell disease remains uncertain. METHODS AND RESULTS: We measured forearm blood flow in 21 patients with sickle cell disease (hemoglobin SS genotype) and 18 black control subjects before and after intra-arterial infusions of acetylcholine, nitroprusside, and the NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA). Endothelium-dependent vasodilation, measured by the percent increase in flow induced by acetylcholine infusion, was significantly greater than in controls (252+/-37% for patients versus 134+/-24% for controls; P<0.0001). However, there was a large sex difference in blood flow responses between female and male patients (340+/-46% versus 173+/-41%; P=0.035). Similarly, basal NO bioactivity, as measured by the percent decrease in flow induced by L-NMMA, was depressed in male compared with female patients (-17+/-5% versus -34+/-4%; P=0.01), as was the response to nitroprusside (86+/-21% versus 171+/-22%; P=0.008). L-NMMA reduced the blood flow response to acetylcholine in women, but not in men. Sex differences in vascular cell adhesion molecule-1 were appreciated, with significant correlations between levels of soluble vascular cell adhesion molecule-1 and blood flow responses to L-NMMA and nitroprusside (r=0.53, P=0.004 and r=-0.66, P<0.001, respectively). CONCLUSIONS: NO bioavailability and NO responsiveness are greater in women than in men with sickle cell disease and determines adhesion molecule expression. Endothelium-dependent blood flows are largely non-NO mediated in male patients. These results provide a possible mechanism for reported sex differences in sickle cell disease morbidity and mortality and provide a basis for novel pharmacological interventions.


Subject(s)
Anemia, Sickle Cell/physiopathology , Nitric Oxide Donors/pharmacokinetics , Nitric Oxide/metabolism , Nitroprusside/pharmacokinetics , Acetylcholine/pharmacology , Adult , Anemia, Sickle Cell/drug therapy , Biological Availability , Biomarkers/blood , Black People , Blood Pressure , Creatinine/blood , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiopathology , Enzyme Inhibitors/pharmacology , Female , Forearm/blood supply , Forearm/physiopathology , Hemodynamics/drug effects , Humans , Hydroxyurea/therapeutic use , Infusions, Intra-Arterial , Male , Middle Aged , Nitric Oxide Donors/administration & dosage , Nitroprusside/administration & dosage , Ornithine/blood , Regional Blood Flow/drug effects , Sex Factors , Vascular Cell Adhesion Molecule-1/blood , Vasodilator Agents/pharmacology , omega-N-Methylarginine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...